on GENSIGHT BIOLOGICS S.A. (EPA:SIGHT)
GenSight Biologics Welcomes William Monteith to the Board of Directors
Paris, June 3, 2024 - GenSight Biologics, a biopharmaceutical company specializing in gene therapies for retinal and neurodegenerative diseases, announces the appointment of William Monteith to its Board of Directors. Monteith took office on May 29, 2024 as an independent Director.
William Monteith brings 43 years of experience in pharmaceutical manufacturing, having held various management positions at Wyeth, Sandoz, Dendreon and Hitachi Chemical. His appointment aims to strengthen the production of LUMEVOQ, a gene therapy for Leber's hereditary optic neuropathy (LHON).
Ivan Tortet, previously interim Financial Director, is appointed Administrative and Financial Director. Tortet actively participated in the recent financing of GenSight Biologics, with experience at Deloitte and various growing high-tech companies.
R. P.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all GENSIGHT BIOLOGICS S.A. news